A Phase 1/2 Study of ARQ 092 in Patients With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome
Phase of Trial: Phase I/II
Latest Information Update: 28 Nov 2018
At a glance
- Drugs Miransertib (Primary)
- Indications Growth disorders; Proteus syndrome
- Focus Adverse reactions
- Sponsors ArQule
- 19 Nov 2018 Planned number of patients changed from 16 to 40.
- 19 Oct 2018 Results presented in the ArQule media release.
- 19 Oct 2018 According to an ArQule media release, preliminary data from this trial was presented at the American Society of Human Genetics (ASHG) 2018 Annual Meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History